These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19195327)

  • 1. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
    Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
    Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
    Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
    Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
    Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
    Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
    Hughes AR; Spreen WR; Mosteller M; Warren LL; Lai EH; Brothers CH; Cox C; Nelsen AJ; Hughes S; Thorborn DE; Stancil B; Hetherington SV; Burns DK; Roses AD
    Pharmacogenomics J; 2008 Dec; 8(6):365-74. PubMed ID: 18332899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
    Small CB; Margolis DA; Shaefer MS; Ross LL
    BMC Infect Dis; 2017 Apr; 17(1):256. PubMed ID: 28399804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
    Saag M; Balu R; Phillips E; Brachman P; Martorell C; Burman W; Stancil B; Mosteller M; Brothers C; Wannamaker P; Hughes A; Sutherland-Phillips D; Mallal S; Shaefer M;
    Clin Infect Dis; 2008 Apr; 46(7):1111-8. PubMed ID: 18444831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
    Stainsby CM; Perger TM; Vannappagari V; Mounzer KC; Hsu RK; Henegar CE; Oyee J; Urbaityte R; Lane CE; Carter LM; Pakes GE; Shaefer MS
    Pharmacotherapy; 2019 Jan; 39(1):40-54. PubMed ID: 30414209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
    Young B; Squires K; Patel P; Dejesus E; Bellos N; Berger D; Sutherland-Phillips DH; Liao Q; Shaefer M; Wannamaker P
    AIDS; 2008 Aug; 22(13):1673-5. PubMed ID: 18670229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
    Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?
    Bracciale L; Santangelo R; Fanti I; Prosperi M; Colafigli M; Di Giambenedetto S; Marchetti S; Di Franco A; Cauda R; De Luca A
    Antivir Ther; 2009; 14(1):99-101. PubMed ID: 19320242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.
    Nieves Calatrava D; Calle-Martín Ode L; Iribarren-Loyarte JA; Rivero-Román A; García-Bujalance L; Pérez-Escolano I; Brosa-Riestra M
    Enferm Infecc Microbiol Clin; 2010 Nov; 28(9):590-5. PubMed ID: 20144493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External quality assessment of HLA-B*5701 reporting: an international multicentre survey.
    Hammond E; Almeida CA; Mamotte C; Nolan D; Phillips E; Schollaardt TA; Gill MJ; Angel JB; Neurath D; Li J; Giulivi T; McIntyre C; Koultchitski G; Wong B; Reis M; Rachlis A; Cole DE; Chew CB; Neifer S; Lalonde R; Roger M; Jeanneau A; Mallal S
    Antivir Ther; 2007; 12(7):1027-32. PubMed ID: 18018760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
    Munderi P; Snowden WB; Walker AS; Kityo C; Mosteller M; Kabuye G; Thoofer NK; Ssali F; Gilks CF; Hughes AR;
    Trop Med Int Health; 2011 Feb; 16(2):200-4. PubMed ID: 21091860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.